Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CRIS, Curis (formerly CBMI) -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (385)	8/10/2001 12:53:14 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 668

Curis Inc 2Q Loss 61c/Shr Dow Jones Newswires Curis Inc. - Cambridge, Mass. 2nd Quar June 30: 2001 2000 Revenue $202,638 $7,471 Net income a (19,277,008) (2,514,016) Avg shrs 31,560,390 11,471,672 Shr earns Net income a (.61) (.22) 6 Months: Revenue $451,803 $677,858 Net income (37,084,237) (8,355,564) Avg shrs 31,497,604 11,369,372 Shr earns Net income (1.18) (.73) Figures in parentheses are losses. a. Includes non-cash amortization of intangible assets and stock based compensation of $9.5 million. Excluding items, the company lost $9.8 million, or 31 cents a share. Curis Inc. (CRIS) reaffirmed its projection for a 2001 loss, excluding non-cash items, of less than $40 million. Second quarter loss, excluding items, was in line with Curis' estimate of about $10 million. Curis' cash and investments as of June 30 were $59 million, which included restricted securities of $1 million. If the upfront cash payments from Micromet and Elan received in early July are considered, Curis' cash and investments are more than $70 million, the company said. "In addition, the Elan transaction also provides us with a line-of-credit to cover Curis' contributions to the Elan joint venture. With these combined resources, Curis has sufficient capital to continue operations into the second quarter of 2003," the company said. Curis, which develops products based on technologies in the field of regenerative medicine, posted cash and cash investments of $59 million at June 30. Company Web site: curis.com